Despite the runaway commercial success of injectables semaglutide and tirzepatide, and a projected global opportunity for obesity pharmacotherapies worth $131Bn by 2028 [2], a number of important issues must be addressed for anti-obesity medicines to fulfil their tremendous potential as public health interventions: Ensuring affordability by patients, in out-of-pocket markets, and by health systems to expand reimbursement of weight loss medicines to ensure equity of access and enable the broad adoption of therapies in eligible patient populations Securing adequate product supply that meets fast growing demand Maintaining weight loss and realising associated, long-term health benefits, e.g., improvements in cardio-metabolic risk factors and co-morbidities Oral obesity treatments will play a critical role in overcoming these challenges, for example, as convenient, long-term maintenance therapy following time-limited induction therapy with injectables
After submission, a licensed provider reviews your information and may adjust or recommend a different medication, route, or protocol if clinically appropriate
After that, the dose is increased incrementally until it reaches the target dose of 2.4 mg weekly
GLP-1 medications are not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
Theres a clear, marked relationship between sensations of fullness in the stomach and hunger signaling from the brain
Compounded semaglutide does not undergo that level of scrutiny
